Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Roth Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $31.00 price target on the biotechnology company’s stock. Roth Capital’s target price would indicate a potential upside of 159.63% from the stock’s current price.
A number of other research firms have also weighed in on CAPR. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Friday, June 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Finally, Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $35.50.
Get Our Latest Research Report on CAPR
Capricor Therapeutics Price Performance
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.42%. The firm had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $3.16 million. During the same quarter last year, the firm posted ($0.31) EPS. Equities analysts anticipate that Capricor Therapeutics will post -1.21 earnings per share for the current year.
Hedge Funds Weigh In On Capricor Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Summit Investment Advisors Inc. lifted its position in Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after buying an additional 1,345 shares during the last quarter. Krilogy Financial LLC raised its stake in shares of Capricor Therapeutics by 9.6% in the first quarter. Krilogy Financial LLC now owns 22,800 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 2,000 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Capricor Therapeutics by 2.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company’s stock valued at $1,079,000 after acquiring an additional 2,314 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Capricor Therapeutics by 22.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 2,361 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Capricor Therapeutics by 20.5% during the 4th quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 2,500 shares during the period. 21.68% of the stock is owned by hedge funds and other institutional investors.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Read More
- Five stocks we like better than Capricor Therapeutics
- Asset Allocation Strategies in Volatile Markets
- Chime’s Smart IPO: Half the Valuation, Double the Strength
- Using the MarketBeat Stock Split Calculator
- Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks
- How to Use the MarketBeat Dividend Calculator
- 3 Catalysts in 7 Days: Archer’s Growth Story Just Accelerated
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.